Skip to main content
Premium Trial:

Request an Annual Quote

Quark Kidney Transplant Drug Receives FDA Orphan Drug Status

Premium

Quark Pharmaceuticals announced this week that the US Food and Drug Administration has granted an orphan drug designation to the company's p53-targeting siRNA QPI-1002 as preventative of delayed graft function in kidney transplant patients.

The designation, Quark said, allows for possible research and development incentives, and qualifies the company for tax credits and a period of market exclusivity following market approval.

Quark said that it has completed dosing in the dose-escalation portion of a phase I/II trial of the drug, and that it has received a positive recommendation from an independent data safety monitoring board to progress the drug to the second portion of the study, which will evaluate the safety and potential clinical activity of QPI-1002.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.